Rozlytrek (entrectinib)

Fantastic learning programme from @DrEzraCohen ! Updates on #NTRK fusions in #thyroidcancer with a focus on: ✅Treatments such as #entrectinib and #larotrectinib ✅ Histopathology ✅Efficacy and safety of treatment Watch and download the slides here👇 https://t.co/KEY6lBsvUT (@PresOnc_Connect)

Dr. @RobertoFerrara_ at #RomeLung23 discusses #NTRK as a viable target in NSCLC with two approved drugs: larotrectinib and entrectinib. Still unraveling primary and acquired resistance but newer agents like repotrectinib showing promise. (@StephenVLiu)

Dr. Lorenza Landi discusses the field for #ROS1 NSCLC at #RomeLung23. Crizotinib and entrectinib are the approved targeted agents but several others in development including repotrectinib and NVL-520. (@StephenVLiu)

Se refiere a Larotrectinib y Entrectinib, 2 fármacos muy activos en tumores con fusiones de NTRK. Y tiene razón: “Nos están denegando posibilidades de vida”, la queja de pacientes con sarcoma por un nuevo fármaco. ⁦@asargasarcoma⁩ ⁦@sanidadgob⁩ https://t.co/jFslumSAwU (@OncoLucus)

New learning programme from @DrEzraCohen ! Updates on #NTRK fusions in #thyroidcancer with a focus on: 1.Treatments such as #entrectinib and #larotrectinib 2. Histopathology 3. Efficacy and safety of treatment Watch and download the slides here👇 https://t.co/phO74f4VJ5 (@ntrkconnectinfo)

► Presentations: - Updated Analysis of the Efficacy and Safety of #Entrectinib in Patients with Locally Advanced/Metastatic #NTRK Fusion-Positive (NTRK-fp) Solid #Tumors Dr. George Demetri, Dana-Farber Cancer Institute @DrSarcoma @DanaFarber @DanaFarberNews @Harvard (@eChinaHealth)

► Presentations: - Updated Analysis of the Efficacy and Safety of #Entrectinib in Patients with Locally Advanced/Metastatic #NTRK Fusion-Positive (NTRK-fp) Solid #Tumors Dr. George Demetri, Dana-Farber Cancer Institute @DrSarcoma @DanaFarber @DanaFarberNews @Harvard (@eChinaHealth)

This is exciting ROS1 fusions are noted in primary brain tumors need more than entrectinib and crizotinib (@shawnkothari)

Check out new programme from @DrEzraCohen on #NTRK fusions in thyroid cancer, with emphasis on using #nextgenerationsequencing to screen for NTRK Click the link for data on targeted therapies like entrectinib & larotrectinib 👇 https://t.co/8it3wIO5kV (@ntrkconnectinfo)

@herbloong presenting an update of #entrectinib efficacy and safety in pts w #ntrk-fusion + #sarcoma: ORR 59%, TRAE leading to discontinuation 5%. When can we be histology-agnostic? (@DCalleMD)

Great update by @herbloong on entrectinib for #NTRK fusion positive sarcomas: 👉🏻ORR 57.7% 👉🏻median duration response 15m 👉🏻median PFS 10m 👉🏻median OS 19m #CTOS2022 #CTOSTweeTOS @ctosociety (@MaddyStrach)

Dr. @JustinGainor reviews the many relevant fusions in NSCLC and the matching targeted agents at #CFS22 like #ALK (his preference is 1L lorlatinib), #RET (pralsetinib and selpercatinib) and #ROS1 (entrectinib, crizotinib) with exciting novel agents in development. (@StephenVLiu)

Growing number of active and promising agents for #ROS1 NSCLC. Crizotinib and entrectinib approved. Lorlatinib with some activity. Repotrectinib in development. Preclinical data for NVL-520 (ARROS-1) with quite impressive numbers. Good to see more options here! #NACLC22 #LCSM (@StephenVLiu)

Excited to share my graduate student's work - "MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC". Notable that MET gene amp occurred via ecDNA. https://t.co/fXYlX8Xcbl @CUCancerCenter @ros1cancer (@rdoebele)

#ASCO22 Last abstract in this section is #9024 from Dr. @alexdrilon highlighting update on larotrectinib in #NTRK NSCLC: RR 83%, mPFS and mOS not reached. Fairly comparable to entrectinib data. Unique toxicities with NTRK inhibition important to remember. (@StephenVLiu)

#ASCO22 Closes with a comment on reimbursement for entrectinib or larotrectinib in #NTRK NSCLC and says it is "crazy" to not reimburse based on efficacy and that waiting for a randomized trial in this rare subtype is inappropriate. #LCSM (@StephenVLiu)

Excelente poster discussion en otros targets en NSCLC. Actualización de eficacia entrectinib B-FAST cohorte ROS1+ (ORR 81.5%, <mPFS y mOS por criterio selección ctDNA+ > tumor burden). Actualización Larotrectinib NTRK+ (ORR 83%,mOS 40.7m). #ASCO2022 @BenjaminBesseMD (@aaoncoclinica)

#ASCO22 Last abstract in this section is #9024 from Dr. @alexdrilon highlighting update on larotrectinib in #NTRK NSCLC: RR 83%, mPFS 14.6m, mOS 40.7m. Fairly comparable to entrectinib data. Unique toxicities with NTRK inhibition important to remember. (@StephenVLiu)

#ASCO22 Closes with a comment on reimbursement for entrectinib or larotrectinib in #NTRK NSCLC and says it is "crazy" to not reimburse based on efficacy and that waiting for a randomized trial in this rare subtype is inappropriate. #LCSM (@StephenVLiu)

BFAST; entrectinib ROS1; efficacy outcomes as expected and similar to tissue genotyped #ASCO22 #LCSM (@DrRiyazShah)

I would recommend mutation testing, at least EGFR/ALK, before giving neoadjuvant immunotherapy. I would also not recommend off label ceritinib for ROS1 NSCLC when crizotinib and entrectinib are approved and available. (@StephenVLiu)

Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with #entrectinib 🔗https://t.co/zFBoMBzXX7 ✏️ @alexdrilon @rdoebele @barlesi @genentech @FoundationATCG @MSKCancerCenter @CUAnschutz #NTRK #NSCLC #cfDNA (@MolOncology)

🎙 Study results "confirm the promising efficacy of entrectinib in NTRK fusion-positive solid tumors," says Christian Rolfo, MD, of @TischCancer @MountSinaiNYC Read more: https://t.co/pXOi3N8cW6 #onctwitter @genentech @ChristianRolfo (@GoHealio)

Study shows positive results for entrectinib in patients with NTRK fusion-positive solid tumors Read more updated analysis from phase 1/2 study in @CCR_AACR here: https://t.co/avifXPmLZJ #oncology @ChristianRolfo @TischCancer @MountSinaiNYC (@HemOncToday)

🎙 Study results "confirm the promising efficacy of entrectinib in NTRK fusion-positive solid tumors," says Christian Rolfo, MD, of @TischCancer @MountSinaiNYC Read more: https://t.co/avifXPmLZJ #onctwitter @genentech @ChristianRolfo (@HemOncToday)

Study shows positive results for entrectinib in patients with NTRK fusion-positive solid tumors Read more updated analysis from phase 1/2 study in @CCR_AACR here: https://t.co/pXOi3N8cW6 #oncology @ChristianRolfo @TischCancer @MountSinaiNYC (@GoHealio)

Study shows positive results for entrectinib in patients with NTRK fusion-positive solid tumors Read more updated analysis from phase 1/2 study in @CCR_AACR here: https://t.co/avifXPmLZJ #oncology @ChristianRolfo @TischCancer @MountSinaiNYC (@HemOncToday)

Encouraging data for #NTRK inhibition in NSCLC presented by Dr. @alexdrilon at #RomeLung22. Both entrectinib and larotrectinib have shown efficacy and manageable toxicity, enough to warrant 1L use. Next gen inhibitors to target resistance include repotrectinib and selitrectinib. (@StephenVLiu)

Dr. Lorenza Landi discusses current management of #ROS1 NSCLC at #RomeLung22. Crizotinib and entrectinib are approved here. Entrectinib may have a CNS edge and showed modest activity after CNS-only progression on crizotinib. Watch for new agents in this space (repotrectinib). (@StephenVLiu)

Patients with NTRK-fp or ROS1-fp #NSCLC solid tumors detected by CTA and the F1L CDx assay demonstrate high response rates to entrectinib. @lungcancerhita @LungCancerDude @LungSummit https://t.co/1lWQrGJKaM (@Dr_Ivanoncologo)

Study suggests entrectinib prolongs survival in ROS1 #TKI naïve patients with ROS1 fusion-positive #NSCLC, with modest activity in patients with #CNS-only progression post-crizotinib 💊🫁 See the study by @alexdrilon, Salvatore Siena & colleagues ➡️ https://t.co/xGgYHOQyaE (@LungSummit)

ICYMI from tonight's @AACR #sarcoma conference keynote speaker - Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors @DrSarcoma @ChristianRolfo #AACRsarcoma22 #clinicaltrials https://t.co/qEJ6RmBq5W (@Marlowe_Tessmer)

🔥Just published @JTOonline by @alexdrilon et al. Long-term Efficacy/Safety of #Entrectinib in #ROS1+ #NSCLC. ORR 68% mDoR 20.5 months, mPFS 15.7 months, mOS 47.8 months. CNS ORR 80% (mDOR 12.9 months, mPFS 8.8 months). #LungCancer #LCSM @OncoAlert 👇🏼 https://t.co/gqhdmrzANq (@RManochakian)

Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with #entrectinib 🔗https://t.co/zFBoMBzXX7 ✏️ @alexdrilon @rdoebele @barlesi @genentech @FoundationATCG @MSKCancerCenter @CUAnschutz #NTRK #NSCLC #ctDNA (@MolOncology)

Long term results of entrectinib in TKI-naive #ROS1 NSCLC now @JTOonline. With median f/u 29m, RR 68%, mDOR 20.5m, mPFS 15.7m, mOS 47.8m. In a separate cohort, modest efficacy seen following CNS-only progression on crizotinib. #LCSM @IASLC https://t.co/DTbkMfTOCP (@StephenVLiu)

Here our E-learning about the importance of identifying #NTRK fusions in patients with #sarcoma and #lungcancer to benefit from targeted #TRK therapy: Entrectinib, larotrectinib and more... #MedEd 👇 https://t.co/jcbUX9X9U2 Thanks: @RobinL_Jones, @ChristianRolfo & Erin Rudzinski (@ntrkconnectinfo)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors ⁦@CCR_AACR⁩ ⁦@AACR⁩ ⁦@DrSarcoma⁩ ⁦@ChristianRolfo⁩ #AACR22 https://t.co/3EHotCJgQC (@VivekSubbiah)

So why not entrectinib for ROS1 or cap/tepo for MET they have excellent CNS? Tolerability could be an issue, but I have mNSCLC on ALKi and RETi with equally severe if not worse toxicities. For me is hard as many unanswered ?s from ADAURA still and even more with other drivers (@PatelOncology)

Dr. @karenkellymd reviews #NTRK in NSCLC at #TTLC22. Two approved and highly active agents available (entrectinib, larotrectinib) with novel agents designed to overcome (and maybe prevent) resistance. (@StephenVLiu)

Entrectinib promising for brain metastases in NTRK fusion-positive solid tumors - https://t.co/vN8mMXOz6f ⁦@ReutersScience⁩ https://t.co/ZXu6cbEuNN (@DrBonillaOnc)

Rozlytrek Offers ‘New Frontier’ for Treating Brain Metastases in NTRK Fusion-Positive Cancers https://t.co/AUBue5HFDf via @curetoday @ChristianRolfo says that brain metastases were very well treated with these compounds. @MountSinaiNYC (@TischCancer)

Demetri et al find that #entrectinib continues to show durable systemic and intracranial responses in patients with NTRK fusion-positive #SolidTumors and has a manageable safety profile in three phase I/II trials. https://t.co/gfEZwOFm0T @DrSarcoma @ChristianRolfo (@CCR_AACR)